Happy New Year! Only a week into 2019, there is no shortage of articles to review and discuss. Â Over the last week, the article that has received the most press is the one documenting [...]
Another year, and an opportunity to reflect on the past year.  It has been another very active year in the field of women’s mental health, with no shortage of articles in this field.  We continue [...]
What’s worse? Prenatal exposure to antidepressant medications or exposure to maternal depression?  Hutchison and colleagues observe that worse executive functioning was observed in the 6-year-old children of mothers with higher levels of depressive symptoms.  Prenatal [...]
Why do we need to identify and treat women with depression who experience during pregnancy? We have long known that postpartum depression can negatively affect the development of children, the large study from Tuovinen and [...]
At this top of the list, we have a study which looked at prenatal exposure to a wide array of psychotropic medications and risk for autism spectrum disorders in the offspring. They found no association [...]
Uguz and colleagues present data that indicate, in a group of women with panic disorder, neonatal outcomes were worse in the women who did not get treatment.  This week’s roundup also features a lot of [...]
The first three articles on this week’s list address the long-term effects of exposure to maternal depression and anxiety on the child.  While many women feel significant pressure to avoid taking psychotropic medications during pregnancy, [...]
Two new studies explore the efficacy of non-pharmacologic treatments for depression during pregnancy. The first uses internet-derived cognitive behavioral therapy (Loughnan et al, 2018) in a group of pregnant women with anxiety and/or depression. The [...]
This week’s offering includes an article published in Pediatrics indicating that cannabis metabolites are found in the breast milk up to 6 days after the last use.  A small prospective study from Wisner and colleagues [...]
Data on the most recent randomized controlled trial of brexanolone, a novel treatment for postpartum depression, were released. (We will review those in greater detail next week.) Â Â Guidelines for the treatment of perimenopausal depression were [...]
